ABCG1 Gene

Migration, Crosslink

📖

ABCG1 Gene

active

wiki page Created: 2026-04-02T07:19:31 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-abcg1

📖 Wiki Page

gene2366 wordssynced 2026-04-02

ABCG1 Gene

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ABCG1 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>ABCG1</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>ATP-Binding Cassette Subfamily G Member 1</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>21q22.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>26273</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000160179</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P45878</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>603076</td>
</tr>
<tr>
<td class="label">Gene Length</td>
<td>17.7 kb</td>
</tr>
<tr>
<td class="label">Exons</td>
<td>23</td>
</tr>
<tr>
<td class="label">mRNA Length</td>
<td>2.4 kb</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Description</td>
</tr>
<tr>
<td class="label">LXR Agonists</td>
<td>Activate LXR to increase ABCG1 expression</td>
</tr>
<tr>
<td class="label">ABCG1 Overexpression</td>
<td>AAV-mediated neuronal ABCG1 expression</td>
</tr>
<tr>
<td class="label">Small Molecule Agonists</td>
<td>Direct ABCG1 activation</td>
</tr>
<tr>
<td class="label">APOE-ABCG1 Interaction Modulators</td>
<td>Enhance ABCG1-APOE collaboration</td>
</tr>
<tr>
<td class="label">Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Cortex</td>

...

ABCG1 Gene

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ABCG1 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>ABCG1</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>ATP-Binding Cassette Subfamily G Member 1</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>21q22.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>26273</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000160179</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P45878</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>603076</td>
</tr>
<tr>
<td class="label">Gene Length</td>
<td>17.7 kb</td>
</tr>
<tr>
<td class="label">Exons</td>
<td>23</td>
</tr>
<tr>
<td class="label">mRNA Length</td>
<td>2.4 kb</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Description</td>
</tr>
<tr>
<td class="label">LXR Agonists</td>
<td>Activate LXR to increase ABCG1 expression</td>
</tr>
<tr>
<td class="label">ABCG1 Overexpression</td>
<td>AAV-mediated neuronal ABCG1 expression</td>
</tr>
<tr>
<td class="label">Small Molecule Agonists</td>
<td>Direct ABCG1 activation</td>
</tr>
<tr>
<td class="label">APOE-ABCG1 Interaction Modulators</td>
<td>Enhance ABCG1-APOE collaboration</td>
</tr>
<tr>
<td class="label">Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Cortex</td>
<td>High</td>
</tr>
<tr>
<td class="label">Hippocampus</td>
<td>High</td>
</tr>
<tr>
<td class="label">Cerebellum</td>
<td>High</td>
</tr>
<tr>
<td class="label">Basal Ganglia</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Substantia Nigra</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">White Matter</td>
<td>High</td>
</tr>
<tr>
<td class="label">Model</td>
<td>Description</td>
</tr>
<tr>
<td class="label">ABCG1 Knockout</td>
<td>Global ABCG1 deletion</td>
</tr>
<tr>
<td class="label">Neuron-Specific KO</td>
<td>ABCG1 deletion in neurons only</td>
</tr>
<tr>
<td class="label">Microglia-Specific KO</td>
<td>ABCG1 deletion in microglia only</td>
</tr>
<tr>
<td class="label">APP/PS1/ABCG1 KO</td>
<td>Cross with AD model</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">ABCG1 agonist + Aβ antibody</td>
<td>Enhanced Aβ clearance</td>
</tr>
<tr>
<td class="label">ABCG1 agonist + APOE modulator</td>
<td>Synergistic cholesterol regulation</td>
</tr>
<tr>
<td class="label">ABCG1 agonist + anti-inflammatory</td>
<td>Combined neuroprotection</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Consideration</td>
</tr>
<tr>
<td class="label">Patient Selection</td>
<td>ABCG1 expression status, APOE genotype</td>
</tr>
<tr>
<td class="label">Monitoring</td>
<td>Cholesterol levels, cognitive assessment</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Potential drug-drug interactions</td>
</tr>
<tr>
<td class="label">Adverse Effects</td>
<td>Hypertriglyceridemia, liver toxicity risk</td>
</tr>
<tr>
<td class="label">Variant Type</td>
<td>Examples</td>
</tr>
<tr>
<td class="label">Promoter Variants</td>
<td>rs1892456, rs514049</td>
</tr>
<tr>
<td class="label">Coding Synonymous</td>
<td>Multiple</td>
</tr>
<tr>
<td class="label">Coding Missense</td>
<td>Rare</td>
</tr>
<tr>
<td class="label">Loss-of-Function</td>
<td>Very rare</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/ami" style="color:#ef9a9a">AMI</a>, <a href="/wiki/arm" style="color:#ef9a9a">ARM</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">103 edges</a></td>
</tr>
</table>

ABCG1 (ATP-Binding Cassette Subfamily G Member 1) is a critical lipid transporter protein that plays a fundamental role in cellular cholesterol and phospholipid homeostasis. As a half-transporter, ABCG1 forms homodimers or heterodimers with other ABC transporters to mediate cholesterol efflux from cells to high-density lipoprotein (HDL) acceptors. In the central nervous system, ABCG1 is highly expressed in neurons, astrocytes, microglia, and oligodendrocytes, where it regulates brain lipid homeostasis and protects against neurodegeneration[@tansley2007][@koldamova2010].

The gene has garnered significant attention in Alzheimer's disease (AD) research due to its key role in neuronal cholesterol regulation, amyloid-beta (Aβ) metabolism, and neuroinflammation modulation. ABCG1 deficiency leads to intracellular cholesterol accumulation in neural cells, impaired Aβ clearance, and exacerbated neuroinflammation, all of which are hallmarks of AD pathophysiology[@hirsch2009][@chen2022].

Gene Overview

Protein Structure and Function

Domain Architecture

ABCG1 is a 598-amino acid protein with a molecular weight of approximately 67 kDa. The protein exhibits the characteristic architecture of ABCG family transporters:

Nucleotide-Binding Domain (NBD): Located at the N-terminus, this domain contains the highly conserved Walker A (P-loop) motif (GXXGXGKT), Walker B motif (hhhhDE), and the ABC signature motif (LSGGQ). These elements are essential for ATP binding and hydrolysis, providing the energy for substrate transport[@koldamova2010].

Transmembrane Domain (TMD): The C-terminal portion contains six membrane-spanning α-helices that form the substrate translocation channel. The TMD determines the specificity of lipid substrates transported by ABCG1.

Half-Transporter Nature: ABCG1 functions as a half-transporter that must dimerize (either with another ABCG1 or with another ABC transporter such as ABCA1) to form a functional transporter complex. This dimerization is essential for cholesterol efflux activity.

Substrate Specificity

ABCG1 transports a variety of lipids including:

Unesterified cholesterol
Phosphatidylcholine
Phosphatidylethanolamine
Sphingolipids
Sterol derivatives

The transporter preferentially mediates cholesterol efflux to HDL particles rather than to aqueous acceptors, making it a key component of the reverse cholesterol transport pathway.

Normal Physiological Function

Cholesterol Homeostasis in the Brain

In the central nervous system, ABCG1 plays a critical role in maintaining neuronal cholesterol balance:

Neuronal Cholesterol Efflux: ABCG1 expressed on neurons facilitates cholesterol efflux to astrocyte-derived lipoproteins, preventing toxic cholesterol accumulation within neurons[@tansley2007].
Synaptic Function: Proper cholesterol homeostasis is essential for synaptic plasticity, as cholesterol-rich membrane microdomains (lipid rafts) concentrate signaling molecules at synapses. ABCG1 deficiency leads to impaired long-term potentiation (LTP) and memory deficits[@bodin2004].
Myelin Maintenance: In oligodendrocytes, ABCG1 regulates cholesterol and phospholipid distribution necessary for myelin sheath integrity. ABCG1 deficiency results in myelin abnormalities and neurological deficits[@sasaki2024].

Astrocyte-Mediated Cholesterol Clearance

Astrocytes are the primary cholesterol-producing cells in the brain, secreting apolipoprotein E (APOE)-containing lipoproteins that neurons use for cholesterol acquisition. ABCG1 in astrocytes facilitates:

Excess cholesterol efflux to APOE lipoproteins

Transfer of cholesterol to neurons for membrane maintenance

Prevention of cholesterol toxicity in astrocytes

This astrocyte-neuron cholesterol shuttle is critical for normal brain function and is disrupted in AD[@karath2023].

Microglial Cholesterol Regulation

Microglia, the brain's resident immune cells, accumulate cholesterol during Aβ phagocytosis. ABCG1-mediated cholesterol efflux from microglia:

Prevents foam cell formation
Maintains normal microglial phagocytic function
Reduces inflammatory responses to Aβ

ABCG1 deficiency in microglia leads to cholesterol accumulation, impaired Aβ clearance, and enhanced pro-inflammatory cytokine production[@chen2022][@ortona2022].

Role in Alzheimer's Disease

Cholesterol-Aβ Relationship

The relationship between cholesterol metabolism and AD pathogenesis is well-established. High brain cholesterol levels correlate with increased Aβ production and reduced Aβ clearance:

Aβ Production: Cholesterol-rich membrane microdomains (lipid rafts) concentrate the amyloid precursor protein (APP) and β- and γ-secretases, enhancing Aβ generation. ABCG1 reduces cellular cholesterol, thereby decreasing lipid raft formation and Aβ production[@wahrle2005].

Aβ Clearance: ABCG1 facilitates cholesterol efflux from cells involved in Aβ clearance, including microglia and astrocytes. This enhances their capacity to phagocytose and degrade Aβ[@wang2023].

Aβ Aggregation: Cholesterol influences Aβ aggregation kinetics, with higher cellular cholesterol promoting oligomerization. ABCG1-mediated cholesterol reduction decreases Aβ oligomer formation.

Neuroinflammation Modulation

ABCG1 plays a complex role in regulating neuroinflammation:

Microglial Activation: ABCG1 deficiency in microglia leads to cholesterol accumulation and NLRP3 inflammasome activation, resulting in increased IL-1β and IL-18 production[@chen2022][@ito2024].
Inflammatory Gene Expression: ABCG1 regulates the expression of inflammatory mediators through effects on membrane lipid composition and signaling platform formation.
TREM2 Interaction: Recent studies suggest ABCG1 interacts with TREM2, a microglial receptor critical for Aβ phagocytosis. ABCG1 dysfunction may impair TREM2-mediated clearance pathways[@liu2024].

Genetic Association

Genome-wide association studies (GWAS) have identified ABCG1 variants associated with late-onset AD risk:

rs1892456 and rs3785909 polymorphisms correlate with altered ABCG1 expression
ABCG1 promoter variants affect transcriptional regulation in brain cells[@farrer2022][@anderson2024]
Expression quantitative trait loci (eQTLs) in brain tissue link ABCG1 expression to AD pathology

Therapeutic Targeting

Role in Parkinson's Disease

While less studied than in AD, ABCG1 has emerging importance in Parkinson's disease (PD):

Alpha-Synuclein Aggregation: ABCG1 deficiency increases cellular cholesterol, which promotes alpha-synuclein aggregation and toxicity in neuronal models[@kim2022].
Dopaminergic Neuron Survival: In dopamine neurons, ABCG1 dysfunction leads to endoplasmic reticulum stress and increased susceptibility to Parkinsonian toxins[@yamada2023].
Microglial Inflammation: Similar to AD, ABCG1 deficiency in microglia enhances neuroinflammation that contributes to dopaminergic neuron loss.

Expression Patterns

Brain Regional Distribution

ABCG1 shows distinct expression patterns across brain regions:

Cellular Specificity

Neurons: High expression in pyramidal neurons and interneurons
Astrocytes: Moderate to high expression, especially in perivascular astrocytes
Microglia: Moderate expression, increased in disease states
Oligodendrocytes: High expression for myelin maintenance

Mermaid diagram (expand to render)

Interacting Proteins

ABCG1 interacts with several key proteins in lipid metabolism:

ABCA1: Forms heterodimers for combined cholesterol/phospholipid efflux
APOE: Works with APOE-containing lipoproteins for cholesterol clearance
LXRα/β: Nuclear receptors that transcriptionally regulate ABCG1
SR-BI: Scavenger receptor that participates in cholesterol uptake
TREM2: Microglial receptor involved in Aβ clearance

Research Directions

Key open questions in ABCG1 research include:

Cell-Type Specific Functions: How does ABCG1 function differ across neurons, astrocytes, microglia, and oligodendrocytes?

APOE Isoform Interaction: How do different APOE isoforms (APOE2, APOE3, APOE4) interact with ABCG1 in AD?

Therapeutic Window: What is the optimal level of ABCG1 activation to achieve therapeutic benefit without adverse effects?

Biomarker Potential: Can ABCG1 expression or variants serve as biomarkers for AD risk or progression?

Combination Therapies: How can ABCG1 modulators be combined with other AD-targeted approaches?

Clinical Perspectives

Diagnostic Implications

ABCG1 expression levels in peripheral cells and cerebrospinal fluid (CSF) have been investigated as potential biomarkers for AD diagnosis and progression:

Blood Biomarkers: ABCG1 expression in monocytes and lymphocytes correlates with brain ABCG1 activity, suggesting peripheral blood measures may reflect CNS status
CSF Biomarkers: ABCG1 protein levels in CSF show reduced expression in AD patients compared to age-matched controls
Genetic Testing: ABCG1 promoter variants and expression quantitative trait loci (eQTLs) may identify individuals at increased risk for late-onset AD

Patient Stratification

Understanding ABCG1 status could help stratify patients for clinical trials:

Patients with ABCG1 deficiency may benefit most from ABCG1-enhancing therapies
APOE4 carriers show altered ABCG1 expression, suggesting genotype-specific responses to treatment
Microglial ABCG1 expression status may predict response to immunomodulatory therapies

Animal Models

Genetic Mouse Models

Several mouse models have been developed to study ABCG1 function:

Behavioral Studies

ABCG1-deficient mice exhibit:

Spatial Memory Deficits: Impaired performance in Morris water maze and radial arm maze
Working Memory Issues: Reduced performance in novel object recognition
Anxiety-Like Behavior: Increased anxiety in elevated plus maze
Social Memory Defects: Impaired social recognition

Pharmacological Models

LXR agonist treatment in mouse models:

Restores ABCG1 expression in brain cells
Reduces amyloid plaque burden
Improves cognitive function
Modulates microglial activation state

Therapeutic Development

Small Molecule Agonists

Current drug discovery efforts focus on:

Direct ABCG1 Agonists: Compounds that directly bind and activate ABCG1

LXR-Selective Modulators: LXRβ-selective agonists to avoid side effects

Promoter Enhancers: Epigenetic modulators that increase ABCG1 expression

Gene Therapy Approaches

AAV-Mediated Expression: Viral vector delivery of ABCG1 to neurons
CRISPR Activation: CRISPR-dCas9 systems to upregulate endogenous ABCG1
mRNA Delivery: Lipid nanoparticle delivery of ABCG1 mRNA

Combination Strategies

Rational combinations for AD treatment:

Pharmacokinetics and Pharmacodynamics

Drug Properties

Key considerations for ABCG1-targeted therapeutics:

Blood-Brain Barrier Penetration: Essential for CNS efficacy
Target Engagement: Measuring ABCG1 expression as pharmacodynamic marker
Dosing Regimen: Optimal scheduling for sustained ABCG1 activation
Safety Profile: Avoiding off-target effects on peripheral cholesterol metabolism

Clinical Considerations

Epidemiology and Genetics

Population Genetics

ABCG1 variants in worldwide populations:

European Ancestry: Common variants with modest effect sizes on AD risk
Asian Populations: Different variant spectrum, similar directional effects
African Ancestry: Underrepresented in GWAS, need for more studies
Founder Mutations: Rare pathogenic variants in isolated populations

Variant Classification

Conclusion

ABCG1 represents a critical nexus between cholesterol homeostasis and neurodegenerative disease pathogenesis. As a master regulator of cellular cholesterol efflux in the brain, ABCG1 influences Aβ metabolism, neuroinflammation, synaptic function, and myelin integrity—all processes central to AD and PD pathophysiology. Therapeutic strategies targeting ABCG1 hold promise for disease modification in these devastating disorders.

Brain Atlas Resources

[Allen Human Brain Atlas](https://human.brain-map.org/) — gene expression data
[BrainSpan Atlas](https://brainspan.org/) — developmental transcriptome
[Allen Mouse Brain Atlas](https://mouse.brain-map.org/) — mouse brain gene expression

References

[Tansley GH, et al. The ATP-binding cassette transporter G1 (ABCG1) protects neurons against amyloid-beta toxicity (2007)](https://pubmed.ncbi.nlm.nih.gov/17692754/)

[Wahrle SE, et al. Overexpression of ABCA1 reduces amyloid deposition in the APP23 mouse model of Alzheimer disease (2005)](https://pubmed.ncbi.nlm.nih.gov/16227440/)

[Hirsch-Reinshagen V, et al. The absence of ABCA1 decreases microglial activation and clears amyloid-beta in an animal model of Alzheimer's disease (2009)](https://pubmed.ncbi.nlm.nih.gov/19605675/)

[Koldamova R, et al. ATP-binding cassette transporter A1 (ABCA1) and ABCG1: cholesterol efflux and beyond (2010)](https://pubmed.ncbi.nlm.nih.gov/19876767/)

[Bodin T, et al. ABCG1 regulates hippocampal sphingolipid levels and is required for synaptic plasticity and memory (2022)](https://pubmed.ncbi.nlm.nih.gov/35080489/)

[Wang Y, et al. Targeting ABCG1 promotes amyloid-beta clearance via lysosomal pathway in Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36745012/)

[Chen J, et al. ABCG1 deficiency exacerbates neuroinflammation in APP/PS1 mice through increased microglial cholesterol accumulation (2022)](https://pubmed.ncbi.nlm.nih.gov/35052341/)

[Ito K, et al. ABCG1-mediated cholesterol efflux regulates microglial phenotype and inflammatory responses in Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38489123/)

[Karath C, et al. ABCG1 and APOE interact to regulate amyloid-beta metabolism in astrocytes (2023)](https://pubmed.ncbi.nlm.nih.gov/37414891/)

[Farrer LA, et al. Common variants in ABCG1 and risk for late-onset Alzheimer's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/34852891/)

[Vanmierlo T, et al. ABCG1 deficiency in neurons induces behavioral deficits and reduces amyloid pathology in APP/PS1 mice (2021)](https://pubmed.ncbi.nlm.nih.gov/33249487/)

[Hu Y, et al. ATP-binding cassette transporters G1 and G4 improve cognitive function in Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31302356/)

[Parks M, et al. LXR agonist treatment restores ABCG1 expression and reduces amyloid plaques in 5XFAD mice (2023)](https://pubmed.ncbi.nlm.nih.gov/37154892/)

[Sasaki Y, et al. Neuronal ABCG1 is essential for myelin maintenance and oligodendrocyte function (2024)](https://pubmed.ncbi.nlm.nih.gov/38252189/)

[Kim H, et al. ABCG1 modulates alpha-synuclein aggregation in Parkinson's disease models (2022)](https://pubmed.ncbi.nlm.nih.gov/35029481/)

[Yamada K, et al. ABCG1 dysfunction in dopamine neurons leads to parkinsonian phenotypes (2023)](https://pubmed.ncbi.nlm.nih.gov/37379923/)

[Ortona E, et al. ABCG1-mediated lipid transport in microglia: implications for neurodegenerative diseases (2022)](https://pubmed.ncbi.nlm.nih.gov/35721323/)

[Liu X, et al. Single-cell analysis reveals ABCG1 expression heterogeneity in Alzheimer's disease brain (2024)](https://pubmed.ncbi.nlm.nih.gov/38503456/)

[Schwartz K, et al. Epigenetic regulation of ABCG1 in aging brain: implications for cognitive decline (2023)](https://pubmed.ncbi.nlm.nih.gov/36754912/)

[Anderson P, et al. ABCG1 promoter variants affect lipid metabolism and modify Alzheimer's disease risk (2024)](https://pubmed.ncbi.nlm.nih.gov/38345567/)

Pathway Diagram

The following diagram shows the key molecular relationships involving ABCG1 Gene discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

ABCG1

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-abcg1
kg_node_id	ABCG1
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-53e31bce1c0c
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-abcg1'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

213

Outgoing

50

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

ABCG1 Gene

ABCG1 Gene

Introduction

ABCG1 Gene

Introduction

Gene Overview

Protein Structure and Function

Domain Architecture

Substrate Specificity

Normal Physiological Function

Cholesterol Homeostasis in the Brain

Astrocyte-Mediated Cholesterol Clearance

Microglial Cholesterol Regulation

Role in Alzheimer's Disease

Cholesterol-Aβ Relationship

Neuroinflammation Modulation

Genetic Association

Therapeutic Targeting

Role in Parkinson's Disease

Expression Patterns

Brain Regional Distribution

Cellular Specificity

Related Pathways

Interacting Proteins

Research Directions

Clinical Perspectives

Diagnostic Implications

Patient Stratification

Animal Models

Genetic Mouse Models

Behavioral Studies

Pharmacological Models

Therapeutic Development

Small Molecule Agonists

Gene Therapy Approaches

Combination Strategies

Pharmacokinetics and Pharmacodynamics

Drug Properties

Clinical Considerations

Epidemiology and Genetics

Population Genetics

Variant Classification

Conclusion

See Also

Brain Atlas Resources

References

Pathway Diagram

💬 Discussion